Coherus BioSciences (NASDAQ:CHRS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.

According to Zacks, “Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California. “

Other analysts have also recently issued research reports about the stock. BidaskClub raised shares of Coherus BioSciences from a “hold” rating to a “buy” rating in a research note on Tuesday, May 8th. Maxim Group set a $18.00 price objective on shares of Coherus BioSciences and gave the company a “buy” rating in a research note on Thursday, May 3rd. ValuEngine raised shares of Coherus BioSciences from a “strong sell” rating to a “sell” rating in a research note on Thursday, April 12th. Finally, Citigroup upped their price objective on shares of Coherus BioSciences from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, March 9th. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $30.11.

CHRS stock opened at $16.10 on Tuesday. The stock has a market cap of $1.02 billion, a PE ratio of -3.59 and a beta of 3.39. The company has a debt-to-equity ratio of -33.10, a current ratio of 4.06 and a quick ratio of 4.06. Coherus BioSciences has a 52 week low of $16.30 and a 52 week high of $16.50.

Coherus BioSciences (NASDAQ:CHRS) last released its earnings results on Thursday, May 10th. The biotechnology company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.04). equities analysts anticipate that Coherus BioSciences will post -2.91 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Swiss National Bank grew its stake in Coherus BioSciences by 10.5% during the 4th quarter. Swiss National Bank now owns 57,700 shares of the biotechnology company’s stock valued at $508,000 after acquiring an additional 5,500 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Coherus BioSciences by 2.7% in the 1st quarter. Wells Fargo & Company MN now owns 218,448 shares of the biotechnology company’s stock valued at $2,413,000 after purchasing an additional 5,658 shares during the last quarter. Northern Trust Corp boosted its holdings in Coherus BioSciences by 1.9% in the 1st quarter. Northern Trust Corp now owns 477,300 shares of the biotechnology company’s stock valued at $5,274,000 after purchasing an additional 8,760 shares during the last quarter. Cornerstone Capital Management Holdings LLC. boosted its holdings in Coherus BioSciences by 34.1% in the 4th quarter. Cornerstone Capital Management Holdings LLC. now owns 35,762 shares of the biotechnology company’s stock valued at $314,000 after purchasing an additional 9,100 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Coherus BioSciences by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 389,013 shares of the biotechnology company’s stock valued at $3,423,000 after purchasing an additional 9,621 shares during the last quarter. 81.38% of the stock is owned by institutional investors.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis.

Get a free copy of the Zacks research report on Coherus BioSciences (CHRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Coherus BioSciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.